Muto Y, Sugihara J, Ohnishi H, Moriwaki H, Nishioka K
First Department of Internal Medicine, Gifu University School of Medicine, Japan.
Gastroenterol Jpn. 1990 Feb;25(1):32-5. doi: 10.1007/BF02785327.
Serial serum samples obtained from 27 patients with fulminant hepatic failure (FHF) in a variety of etiology were tested for anti-hepatitis C virus antibody (anti-HCV). Seven out of 10 patients (70%) with FHF due to hepatitis B virus (HBV) infection were positive for anti-HCV, showing a significantly higher rate than that in acute HBV hepatitis (0/17, 0%): In particular, all 3 post-transfusion HBV-FHF cases were found to be positive for the antibody. The incidence of anti-HCV in sporadic non-A non-B (NANB)-FHF patients (7/11, 64%) tended to be greater than that in acute sporadic NANB hepatitis as recently surveyed in this country. In addition, anti-HCV was also detected in a patient with hepatitis A virus (HAV)-FHF and in 2 out of 4 drug-induced FHF patients. Moreover, anti-HCV appeared earlier in FHF (median; 27.5 days, n = 9) regardless of etiology, when compared to acute NANB hepatitis (3 to 6 months). Hence, co-infection and/or superinfection of HCV with enhanced antibody response may play an important role in the development of this fatal disease.
对27例各种病因所致暴发性肝衰竭（FHF）患者的系列血清样本进行了抗丙型肝炎病毒抗体（抗-HCV）检测。10例因乙型肝炎病毒（HBV）感染导致FHF的患者中有7例（70%）抗-HCV呈阳性，其阳性率显著高于急性HBV肝炎患者（0/17，0%）：特别是所有3例输血后HBV-FHF病例的抗体检测均为阳性。散发性非甲非乙（NANB）-FHF患者中抗-HCV的发生率（7/11，64%）高于我国近期调查的急性散发性NANB肝炎患者。此外，在1例甲型肝炎病毒（HAV）-FHF患者以及4例药物性FHF患者中的2例也检测到了抗-HCV。而且，与急性NANB肝炎（3至6个月）相比，无论病因如何，抗-HCV在FHF患者中出现得更早（中位数；27.5天，n = 9）。因此，HCV合并感染和/或重叠感染以及增强的抗体反应可能在这种致命疾病的发生发展中起重要作用。
